Zevra Therapeutics, Inc. (ZVRA) key performance indicators and operating metrics (19 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| MIPLYFFA market access | 69.00 percent | FY2026-Q2 |
| MIPLYFFA prescription enrollment forms | 14.00 | FY2026-Q2 |
| OLPRUVA net revenue | 200K | FY2026-Q2 |
| MIPLYFFA net revenue | 30.2M | FY2026-Q2 |
| Total net revenue growth | 53.00 percent | FY2026-Q2 |
| OLPRUVA market access | 81.00 percent | FY2025-Q3 |
| OLPRUVA new patient enrollments | 1.00 | FY2025-Q2 |
| DiSCOVER trial total patients enrolled | 66.00 | FY2026-Q2 |
| Global Expanded Access Program patients enrolled | 132.00 | FY2026-Q2 |
| MIPLYFFA total prescription enrollment forms since launch | 184.00 | FY2026-Q2 |
| DiSCOVER trial patients enrolled | 10.00 | FY2026-Q1 |
| Royalties and other reimbursements under the AZSTARYS license agreement | 1.1M | FY2026-Q1 |
| Arimoclomol Global Expanded Access Program reimbursements | 9M | FY2026-Q2 |
| Product net revenue | 21.8M | FY2025-Q2 |
Back to ZVRA overview · ZVRA earnings · ZVRA holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.